Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients

Infection, Genetics and Evolution

Volumn 9, Issue 4, 2009, Pages 646-652

  Yaotsè, Dagnra Anoumou ^a   Nicole, Vidal ^b   Roch, Niama Fabien ^b   Mireille, Prince David ^a   Eric, Delaporte ^b   Martine, Peeters ^b  

^a Centre National de Référence des tests VIH IST   (Togo)

^b UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Antiretroviral resistance; HIV 1 diversity; Togo

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARAGINE; LEUCINE; LYSINE; METHIONINE; PROTEINASE; THREONINE; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE CLUSTER; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; TOGO; VIRUS IDENTIFICATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; CHILD; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENES, ENV; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA; TOGO;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68649116970     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2009.04.002     Document Type: Article

References (32)

1. Baeten J.M., Chohan B., Lavreys L., Chohan V., McClelland R.S., Certain L., Mandaliya K., Jaoko W., and Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 195 (2007) 1177-1180
2. Baldrich-Rubio E., Anagonou S., Stirrups K., Lafia E., Candotti D., Lee H., and Allain J.P. A complex human immunodeficiency virus type 1 A/G/J recombinant virus isolated from a seronegative patient with AIDS from Benin, West Africa. J. Gen. Virol. 82 (2001) 1095-1106
3. Bennett D.E., Bertagnolio S., Sutherland D., and Gilks C.F. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13 Suppl 2 (2008) 1-13
4. Delgado E., Ampofo W.K., Sierra M., Torpey K., Pérez-Alvarez L., Bonney E.Y., Mukadi Y.D., Lartey M., Nyarko C., Amenyah R.N., Thomson M., and Nájera R. High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study. J. Acquir. Immune Defic. Syndr. 48 (2008) 599-606
5. Derache A., Maiga A.I., Traore O., Akonde A., Cisse M., Jarrousse B., Koita V., Diarra B., Carcelain G., Barin F., Pizzocolo C., Pizarro L., Katlama C., Calvez V., and Marcelin A.G. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J. Antimicrob. Chemother. 62 (2008) 456-463
6. Gilks C.F., Crowley S., Ekpini R., Gove S., Perriens J., Souteyrand Y., Sutherland D., Vitoria M., Guerma T., and De Cock K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (2006) 505-510
7. Gupta R.K., and Pillay D. HIV resistance and the developing world. Int. J. Antimicrob. Agents 29 (2007) 510-517
8. Hamel D.J., Sankalé J.L., Eisen G., Meloni S.T., Mullins C., Gueye-Ndiaye A., Mboup S., and Kanki P.J. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res. Hum. Retroviruses 23 (2007) 1189-1196
9. Hamers R.L., Derdelinckx I., van Vugt M., Stevens W., Rinke, de Wit T.F., Schuurman R., and on behalf of the PharmAccess African Studies to Evaluate Resistance (PASER) programme. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir. Ther. 13 (2008) 625-639
10. Hemelaar J., Gouws E., Ghys P.D., and Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 (2006) W13-W23
11. Herbinger K.H., Gerhardt M., Piyasirisilp S., Mloka D., Arroyo M.A., Hoffmann O., Maboko L., Birx D.L., Mmbando D., McCutchan F.E., and Hoelscher M. Frequency of HIV type 1 dual infection and HIV diversity: analysis of low- and high-risk populations in Mbeya region, Tanzania. AIDS Res. Hum. Retroviruses 22 (2006) 599-606
12. Kanki P.J., Hamel D.J., Sankalé J.L., Hsieh C., Thior I., Barin F., Woodcock S.A., Guèye-Ndiaye A., Zhang E., Montano M., Siby T., Marlink R., NDoye I., Essex M.E., and MBoup S. Human immunodeficiency virus type 1 subtypes differ in disease progression. J. Infect. Dis. 179 (1999) 68-73
13. Laukkanen T., Carr J.K., Janssens W., Liitsola K., Gotte D., McCutchan F.E., Op de Coul E., Cornelissen M., Heyndrickx L., van der Groen G., and Salminen M.O. Virtually full-length subtype F and F/D recombinant HIV-1 from Africa and South America. Virology 269 (2000) 95-104
14. Manigart O., Courgnaud V., Sanou O., Valéa D., Nagot N., Meda N., Delaporte E., Peeters M., and Van de Perre P. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS 18 (2004) 1645-1651
15. Mamadou S., Montavon C., Ben A., Djibo A., Rabiou S., Mboup S., Delaporte E., and Peeters M. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Res. Hum. Retroviruses 18 (2002) 723-726
16. McCutchan F.E. Global epidemiology of HIV. J. Med. Virol. 78 (2006) S7-S12
17. Niama F.R., Toure-Kane C., Vidal N., Obengui P., Bikandou B., Ndoundou Nkodia M.Y., Montavon C., Diop-Ndiaye H., Mombouli J.V., Mokondzimobe E., Diallo A.G., Delaporte E., Parra H.J., Peeters M., and Mboup S. HIV-1 subtypes and recombinants in the Republic of Congo. Infect. Genet. Evol. 6 (2006) 337-343
18. Ouédraogo-Traoré R., Montavon C., Sanou T., Vidal N., Sangaré L., Sanou I., Soudré R., Mboup S., Delaporte E., and Peeters M. CRF06-cpx is the predominant HIV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina Faso. AIDS 17 (2003) 441-442
19. Peeters M., Toure-Kane C., and Nkengasong J. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, and vaccine development and trials. AIDS 17 (2003) 2547-2560
20. Paraskevis D., Magiorkinis E., Magiorkinis G., Anastassopoulou C., Lazanas M., Chrysos G., Vandamme A.M., and Hatzakis A. Molecular characterization of a complex, recombinant human immunodeficiency virus type 1 (HIV-1) isolate (A/G/J/K/?): evidence to support the existence of a novel HIV-1 subtype. J. Gen. Virol. 82 (2001) 2509-2514
21. Powell R.L., Urbanski M.M., Burda S., Kinge T., and Nyambi P.N. High frequency of HIV-1 dual infections among HIV-positive individuals in Cameroon, West Central Africa. J. Acquir. Immune Defic. Syndr. 50 (2009) 84-92
22. Sankalé J.L., Langevin S., Odaibo G., Meloni S.T., Ojesina A.I., Olaleye D., and Kanki P. The complexity of circulating HIV type 1 strains in Oyo state, Nigeria. AIDS Res. Hum. Retroviruses 23 (2007) 1020-1025
23. Shafer R.W., Rhee S.Y., and Bennett D.E. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir. Ther. 13 Suppl 2 (2008) 59-68
24. Tebit D.M., Ganame J., Sathiandee K., Nagabila Y., Coulibaly B., and Krausslich H.G. Diversity of HIV in rural Burkina Faso. J. Acquir. Immune Defic. Syndr. 43 (2006) 144-152
25. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
26. Toni T., Masquelier B., Minga A., Anglaret X., Danel C., Coulibaly A., Chenal H., Dabis F., Salamon R., Fleury H.J., and Primo-CI ANRS 1220 Study Group. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: a 4- year survey, 2002-2006. AIDS Res. Hum. Retroviruses 23 (2007) 1155-1160
27. Vasan A., Renjifo B., Hertzmark E., Chaplin B., Msamanga G., Essex M., Fawzi W., and Hunter D. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin. Infect. Dis. 42 (2006) 843-852
28. Vergne L., Diagbouga S., Kouanfack C., Aghokeng A., Butel C., Laurent C., Noumssi N., Tardy M., Sawadogo A., Drabo J., Hien H., Zekeng L., Delaporte E., and Peeters M. HIV-1 drug resistance mutations among antiretroviral-naive newly diagnosed patients in Africa before scaling up programs: examples of Burkina Faso and Cameroon. Antivir. Ther. 11 (2006) 575-579
29. Vidal N., Peeters M., Mulanga-Kabeya C., Nzilambi N., Robertson D., Ilunga W., Sema H., Tshimanga K., Bongo B., and Delaporte E. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J. Virol. 74 (2000) 10498-10507
30. Vidal N., Mulanga C., Bazepeo S.E., Mwamba J.K., Tshimpaka J.W., Kashi M., Mama N., Laurent C., Lepira F., Delaporte E., and Peeters M. Distribution of HIV-1variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. J. Acquir. Immune Defic. Syndr. 40 (2005) 456-462
31. Wainberg M.A. HIV-1 subtype distribution and the problem of drug resistance. AIDS 18 Suppl 3 (2004) S63-S68
32. Worobey M., Gemmel M., Teuwen D.E., Haselkorn T., Kunstman K., Bunce M., Muyembe J.J., Kabongo J.M., Kalengayi R.M., Van Marck E., Gilbert M.T., and Wolinsky S.M. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455 (2008) 661-664